Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Acadia Pharmaceuticals Inc’s stock clocked out at $18.35, down -1.45% from its previous closing price of $18.62. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 1.91 million shares were traded. ACAD stock price reached its highest trading level at $18.93 during the session, while it also had its lowest trading level at $18.3.
Ratios:
To gain a deeper understanding of ACAD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 47.62. For the most recent quarter (mrq), Quick Ratio is recorded 1.86 and its Current Ratio is at 2.04. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on June 27, 2024, initiated with a Outperform rating and assigned the stock a target price of $31.
On March 12, 2024, Needham reiterated its Buy rating and also upped its target price recommendation from $36 to $32.
Mizuho Downgraded its Buy to Neutral on March 12, 2024, whereas the target price for the stock was revised from $39 to $25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 10 ’24 when Schneyer Mark C. sold 975 shares for $14.79 per share. The transaction valued at 14,420 led to the insider holds 34,564 shares of the business.
DAVIS STEPHEN sold 11,427 shares of ACAD for $193,573 on May 02 ’24. The CEO now owns 155,231 shares after completing the transaction at $16.94 per share. On May 02 ’24, another insider, Schneyer Mark C., who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 3,503 shares for $16.94 each. As a result, the insider received 59,341 and left with 32,053 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 3074744320 and an Enterprise Value of 2620925184. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.73 while its Price-to-Book (P/B) ratio in mrq is 6.52. Its current Enterprise Value per Revenue stands at 3.221 whereas that against EBITDA is 431.855.
Stock Price History:
Over the past 52 weeks, ACAD has reached a high of $33.99, while it has fallen to a 52-week low of $14.55. The 50-Day Moving Average of the stock is 16.50%, while the 200-Day Moving Average is calculated to be -13.87%.
Shares Statistics:
It appears that ACAD traded 1.71M shares on average per day over the past three months and 1873566 shares per day over the past ten days. A total of 164.65M shares are outstanding, with a floating share count of 164.01M. Insiders hold about 0.73% of the company’s shares, while institutions hold 97.91% stake in the company. Shares short for ACAD as of 1719532800 were 11926668 with a Short Ratio of 6.97, compared to 1717113600 on 12135862. Therefore, it implies a Short% of Shares Outstanding of 11926668 and a Short% of Float of 9.770001.